Steven Y. Hua

1.6k total citations · 1 hit paper
37 papers, 1.2k citations indexed

About

Steven Y. Hua is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Steven Y. Hua has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Immunology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Steven Y. Hua's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Biosimilars and Bioanalytical Methods (8 papers) and Pharmaceutical studies and practices (7 papers). Steven Y. Hua is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Biosimilars and Bioanalytical Methods (8 papers) and Pharmaceutical studies and practices (7 papers). Steven Y. Hua collaborates with scholars based in United States, Canada and United Kingdom. Steven Y. Hua's co-authors include Brian G. Feagan, Douglas C. Wolf, Silvio Danese, William J. Sandborn, Geert D’Haens, Denesh K. Chitkara, AnnKatrin Petersen, Lorna Charles, Subrata Ghosh and Ji Hwan Lee and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Steven Y. Hua

37 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Y. Hua United States	16	336	305	277	229	211	37	1.2k
Olagunju Ogunbiyi United Kingdom	11	281 0.8×	216 0.7×	419 1.5×	169 0.7×	215 1.0×	18	1.2k
Etsuko Maruya Japan	24	240 0.7×	790 2.6×	216 0.8×	142 0.6×	101 0.5×	72	1.8k
Nathanael L. Dirks United States	9	528 1.6×	403 1.3×	150 0.5×	422 1.8×	239 1.1×	21	1.1k
Gian Lodovico Rapaccini Italy	24	503 1.5×	229 0.8×	147 0.5×	1.1k 4.6×	90 0.4×	51	1.9k
Nadežda Basara Germany	23	74 0.2×	420 1.4×	520 1.9×	226 1.0×	131 0.6×	70	2.1k
Jennifer Hodge United States	11	158 0.5×	384 1.3×	223 0.8×	190 0.8×	40 0.2×	15	1.1k
Pincas Bitterman United States	23	194 0.6×	158 0.5×	431 1.6×	303 1.3×	77 0.4×	73	2.1k
Evelyne T. Edwards United States	5	276 0.8×	606 2.0×	161 0.6×	389 1.7×	105 0.5×	6	1.9k
Larry Lo United States	11	153 0.5×	426 1.4×	155 0.6×	195 0.9×	84 0.4×	18	1.2k
Wolfgang Kraaz Sweden	19	261 0.8×	238 0.8×	255 0.9×	391 1.7×	44 0.2×	34	1.3k

Countries citing papers authored by Steven Y. Hua

Since Specialization

Citations

This map shows the geographic impact of Steven Y. Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Y. Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Y. Hua more than expected).

Fields of papers citing papers by Steven Y. Hua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Y. Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Y. Hua. The network helps show where Steven Y. Hua may publish in the future.

Co-authorship network of co-authors of Steven Y. Hua

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Y. Hua. A scholar is included among the top collaborators of Steven Y. Hua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Y. Hua. Steven Y. Hua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hua, Steven Y., Zhiyong Dong, Hui Wang, & Tong Liu. (2025). Global, regional, and national burden of ischemic stroke in older adults (≥60 years) from 1990 to 2021 and projections to 2030. Frontiers in Neurology. 16. 1567609–1567609. 1 indexed citations

Saxena, Amit, et al.. (2023). POS1128 ZETOMIPZOMIB (KZR-616) TREATMENT RESULTS IN CLINICALLY MEANINGFUL RENAL RESPONSES IN PATIENTS WITH LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 82. 891–892. 3 indexed citations

Feagan, Brian G., William J. Sandborn, Silvio Danese, et al.. (2020). Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. The Lancet. Gastroenterology & hepatology. 5(9). 819–828. 107 indexed citations

Gann, Peter H., Ryan Deaton, Margaret H. Collins, et al.. (2020). An anti–IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results. Journal of Allergy and Clinical Immunology. 146(2). 367–376.e3. 37 indexed citations

Dellon, Evan S., Margaret H. Collins, Marc E. Rothenberg, et al.. (2020). Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology. 19(3). 473–483.e17. 61 indexed citations

Feagan, Brian G., William J. Sandborn, Geert D’Haens, et al.. (2019). P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial. Journal of Crohn s and Colitis. 13(Supplement_1). S464–S464. 2 indexed citations

Rosen, Lee S., Robert Wesolowski, Raffaele Baffa, et al.. (2019). A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors. Investigational New Drugs. 38(1). 120–130. 41 indexed citations

Cohen, Stanley, Rieke Alten, Hideto Kameda, et al.. (2018). A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Research & Therapy. 20(1). 155–155. 45 indexed citations

Hirano, Ikuo, Margaret H. Collins, Yehudith Assouline-Dayan, et al.. (2018). A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY RPC4046 IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Annals of Allergy Asthma & Immunology. 121(5). S15–S15. 1 indexed citations

10.

Fleischmann, Roy, Rieke Alten, Margarita Pileckytė, et al.. (2018). A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis Research & Therapy. 20(1). 178–178. 42 indexed citations

11.

Shapiro, Geoffrey I., Ulka N. Vaishampayan, Patricia LoRusso, et al.. (2017). First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investigational New Drugs. 35(3). 315–323. 32 indexed citations

12.

Yin, Donghua, Chandrasekhar Udata, Steven Y. Hua, et al.. (2015). Mo1221 Comparative Assessments of PF-06438179, a Potential Biosimilar, and Infliximab in a Phase 1 Pharmacokinetic Study. Gastroenterology. 148(4). S–642. 3 indexed citations

13.

Xu, Siyan, Steven Y. Hua, R. G. Menton, et al.. (2014). Inference of bioequivalence for log‐normal distributed data with unspecified variances. Statistics in Medicine. 33(17). 2924–2938. 1 indexed citations

14.

Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583. 119 indexed citations

15.

Hua, Steven Y., et al.. (2010). Multivariate Failure Time Analysis when only the Time to First Failure is Observed. Communications in Statistics - Simulation and Computation. 40(1). 113–128. 1 indexed citations

16.

Verhoef, Gregor, Mitchell R. Smith, Peter Johnson, et al.. (2010). Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma. Ghent University Academic Bibliography (Ghent University). 2 indexed citations

17.

Whitson, Jess T., John D. Roarty, Lingam Vijaya, et al.. (2008). Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial. Journal of American Association for Pediatric Ophthalmology and Strabismus. 12(3). 239.e1–239.e11. 21 indexed citations

18.

Kaback, Martin B., Stephen V. Scoper, Steven Y. Hua, et al.. (2008). Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5%. Ophthalmology. 115(10). 1728–1734.e2. 38 indexed citations

19.

Henry, J, et al.. (2006). Comparison of the Safety and IOP–Lowering Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination to the Concomitant Administration of Xalatan® and Timolol 0.5%. Investigative Ophthalmology & Visual Science. 47(13). 446–446. 2 indexed citations

20.

Sattar, Syed A., et al.. (2000). Activity of an Alcohol-Based Hand Gel Against Human Adeno-, Rhino-, and Rotaviruses Using the Fingerpad Method. Infection Control and Hospital Epidemiology. 21(8). 516–519. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact